Nanosized Bilosomes as a Potential Platform for Improved Therapeutic Efficacy of Capecitabine Against Colon Cancer in Rats: Formulation, Evaluation, and Optimization.
10 affiliations
- 1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, New Valley University, Al-Wadi Al-Gadid 72511, Egypt.
- 2Department of Pharmaceutics, Faculty of Pharmacy, Port Said University, Port Said 42515, Egypt.
- 3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Al Azhar University, Assiut Branch, Assiut 71524, Egypt.
- 4Michael Sayegh Faculty of Pharmacy, Aqaba University of Technology, Aqaba 11191, Jordan.
- 5Department of Pharmaceutics, Faculty of Pharmacy, East Port Said National University, Por Fouad 42526, Egypt.
- 6Medical Emergency, Aqaba Modern Hospital, Aqaba 77110, Jordan.
- 7Department of Pharmacology and Toxicology, Faculty of Pharmacy, Port Said University, Port Said 42526, Egypt.
- 8Pharmacology & Toxicology Department, Clinical Pharmacy Program, East Port Said National University, Port Said 42526, Egypt.
- 9Department of Pharmaceutics, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
- 10Department of Biochemistry, Faculty of Pharmacy, Port Said University, Port Said 42515, Egypt.
Abstract
Background/Objectives: Colorectal cancer is a leading cause of global cancer-related mortality. Capecitabine, a 5-fluorouracil prodrug, effectively targets colorectal cancer but suffers from an extremely short half-life, requiring frequent administration. Bilosomes (membrane-stabilized bile salts) are vesicular systems that improve gastrointestinal stability, prevent drug leakage, and extend residence time. This study aimed to fabricate and characterize capecitabine-loaded nanosized bilosomes to overcome the pharmacokinetic limitations and systemic toxicities of conventional capecitabine therapy. By leveraging bile salt-stabilized vesicular systems, we seek to provide sustained capecitabine release, improve gastrointestinal permeability, and enhance therapeutic efficacy against colorectal cancer. We also assessed the anticancer potential of capecitabine-loaded nanosized bilosomes by measuring diagnostic and prognostic biomarkers, including cancer embryonic antigen, carbohydrate antigen 19.9, matrix metalloproteinase-9, and vascular endothelial growth factor A, to evaluate their impact on tumor progression, extracellular matrix degradation, and angiogenesis. Methods: In a 3² full factorial design, nine capecitabine-loaded bilosomes were generated utilizing a central composite design within the framework of response surface methodology. Entrapment efficiency, in vitro drug release and its kinetics, vesicle size, zeta potential, and their kinetics were evaluated. The optimized capecitabine-loaded nanosized bilosomes formulation was subjected to further investigations, such as Fourier transform infra-red spectroscopy, differential scanning calorimetry, X-ray diffractometry study, stability studies, pharmacokinetic study, and in vivo studies, including detection of matrix metalloproteinase-9 and vascular endothelial growth factor A by Real-Time polymerase chain reaction, evaluation of colon biomarker, and examination of colon tissue through histopathology. Results: The prepared capecitabine-loaded bilosomes were nanosized spheres with suitable entrapment efficiency and a high zeta potential. After treatment with capecitabine-loaded bilosomes, the data collected from living organisms indicated a notable reduction in the serum values of carbohydrate antigen 19.9 and cancer embryonic antigen, gene expression values of matrix metalloproteinase-9 and vascular endothelial growth factor A. Histopathological study showed almost complete restoration of colonic features with a lesser extent of epithelial lining and crypt dysplasia. Conclusions: The present study findings demonstrate that capecitabine-loaded bilosomes possess high anti-tumor activity against colorectal cancer.
Related
- Closed-loop formulation–process optimization under unknown feasibility for extended-release pellets
- Optimization of the Composite Formulation for Rotational Molding Based on Recycled Polyethylene and Antioxidants
- Optimization of Contents of Three Raw Clay Materials in Formulation of a Porcelain
- Sustainable Polyvinyl Alcohol/Carnauba Wax Films: D-Optimal Formulation Optimization for Improved Water Resistance
- Granulated Ammonium Alginate as a Functional Sodium-Sequestration Agent: Formulation Optimization Using Box–Behnken Design
BibTeX
@article{mostafa2026nanosized,
title = {{Nanosized Bilosomes as a Potential Platform for Improved Therapeutic Efficacy of Capecitabine Against Colon Cancer in Rats: Formulation, Evaluation, and Optimization.}},
author = {Mahmoud Elkot Mostafa and Abd El Hakim Ramadan and Ahmed A El-Shenawy and Islam Kamal and Loiy B Hamed and Ahmed S Saad and Ayman Salama and Mohamed Mahrous and Gamal M K Atwa},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/ph19101531},
url = {https://europepmc.org/article/MED/42943228},
note = {CC BY},
}
RIS
TY - JOUR
TI - Nanosized Bilosomes as a Potential Platform for Improved Therapeutic Efficacy of Capecitabine Against Colon Cancer in Rats: Formulation, Evaluation, and Optimization.
AU - Mahmoud Elkot Mostafa
AU - Abd El Hakim Ramadan
AU - Ahmed A El-Shenawy
AU - Islam Kamal
AU - Loiy B Hamed
AU - Ahmed S Saad
AU - Ayman Salama
AU - Mohamed Mahrous
AU - Gamal M K Atwa
PY - 2026
DA - 2026/09/27
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101531
UR - https://europepmc.org/article/MED/42943228
AB - Background/Objectives: Colorectal cancer is a leading cause of global cancer-related mortality. Capecitabine, a 5-fluorouracil prodrug, effectively targets colorectal cancer but suffers from an extremely short half-life, requiring frequent administration. Bilosomes (membrane-stabilized bile salts) are vesicular systems that improve gastrointestinal stability, prevent drug leakage, and extend residence time. This study aimed to fabricate and characterize capecitabine-loaded nanosized bilosomes to overcome the pharmacokinetic limitations and systemic toxicities of conventional capecitabine therapy. By leveraging bile salt-stabilized vesicular systems, we seek to provide sustained capecitabine release, improve gastrointestinal permeability, and enhance therapeutic efficacy against colorectal cancer. We also assessed the anticancer potential of capecitabine-loaded nanosized bilosomes by measuring diagnostic and prognostic biomarkers, including cancer embryonic antigen, carbohydrate antigen 19.9, matrix metalloproteinase-9, and vascular endothelial growth factor A, to evaluate their impact on tumor progression, extracellular matrix degradation, and angiogenesis. Methods: In a 3² full factorial design, nine capecitabine-loaded bilosomes were generated utilizing a central composite design within the framework of response surface methodology. Entrapment efficiency, in vitro drug release and its kinetics, vesicle size, zeta potential, and their kinetics were evaluated. The optimized capecitabine-loaded nanosized bilosomes formulation was subjected to further investigations, such as Fourier transform infra-red spectroscopy, differential scanning calorimetry, X-ray diffractometry study, stability studies, pharmacokinetic study, and in vivo studies, including detection of matrix metalloproteinase-9 and vascular endothelial growth factor A by Real-Time polymerase chain reaction, evaluation of colon biomarker, and examination of colon tissue through histopathology. Results: The prepared capecitabine-loaded bilosomes were nanosized spheres with suitable entrapment efficiency and a high zeta potential. After treatment with capecitabine-loaded bilosomes, the data collected from living organisms indicated a notable reduction in the serum values of carbohydrate antigen 19.9 and cancer embryonic antigen, gene expression values of matrix metalloproteinase-9 and vascular endothelial growth factor A. Histopathological study showed almost complete restoration of colonic features with a lesser extent of epithelial lining and crypt dysplasia. Conclusions: The present study findings demonstrate that capecitabine-loaded bilosomes possess high anti-tumor activity against colorectal cancer.
SN - 1424-8247
ER -